Sequent Scientific (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Sequent Scientific Limited |
|||
|
Price: ₹175.36 | ||
| 52 Week Low: ₹92.05 52 Week High: ₹240.70 |
|||
| Market Capital: 2,735.55 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Sequent Scientific Share Price Target For 2024
- 1.1.1: Sequent Scientific Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Sequent Scientific Share Price Target For 2025
- 1.2.1: Sequent Scientific Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Sequent Scientific Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Sequent Scientific Brief Company Overview
- 4: Sequent Scientific Financial Performance
- 4.0.1: Is Sequent Scientific A Good Buy For Long Term?
To predict the Sequent Scientific's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Sequent Scientific Share Price Target For 2024
The line chart displays the monthly closing prices of Sequent Scientific with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Sequent Scientific shares in 2024, see the table below.
Sequent Scientific Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 185.65 (+5.86%) | Price Action: 19 Dec 2024 High |
| 2024 Target 2 | 183.72 (+4.76%) | Price Action: 23 Oct 2024 High |
| 2024 Target 1 | 181.82 (+3.68%) | Technical Indicator: MA100 |
| Current Price | 175.36 | Sequent Scientific's share price as of 23 Dec 2024 |
| Stop Loss 1 | 172.35 (-1.72%) | Price Action: 28 Oct 2024 High |
| Stop Loss 2 | 168.72 (-3.79%) | Price Action: Jan 2021 Low |
| Stop Loss 3 | 166.43 (-5.09%) | Price Action: Nov 2020 High |
Short-Term Technical Outlook
Current Technical Position: Sequent Scientific is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹192.65 serves as the nearest technical reference point.
Historical Returns: 3-month: -23.7% | 6-month: +51.54% | 1-year: +55.77%
Sequent Scientific Share Price Target For 2025
The line chart displays the monthly closing prices of Sequent Scientific with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Sequent Scientific shares in 2025, see the table below.
Sequent Scientific Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 281.01 (+60.24%) | Price Action: Chart |
| 2025 Target 2 | 275.77 (+57.25%) | Fibonacci Extension Level 123.60% |
| 2025 Target 1 | 271.83 (+55.01%) | Fibonacci Extension Level 64.90% |
| Current Price | 175.36 | Sequent Scientific's share price as of 23 Dec 2024 |
| Stop Loss 1 | 152.09 (-13.27%) | Technical Indicator: MA200 |
| Stop Loss 2 | 150.5 (-14.18%) | Price Action: Dec 2021 Low |
| Stop Loss 3 | 148.52 (-15.31%) | Technical Indicator: MA250 |
Long-Term Technical Outlook
52-Week Range Analysis: Sequent Scientific is currently trading at 56.0% of its 52-week range (₹92.05 - ₹240.7).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +55.77% | 3-year: +10.1% | 5-year: +151.19%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Sequent Scientific Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹175.36 | ||
| 2024 | ₹230.76 | +31.59% | ₹234.22 |
| 2025 | ₹346.11 | +49.98% | ₹363.83 |
| 2026 | ₹487.67 | +40.9% | ₹494.99 |
| 2027 | ₹594.73 | +21.95% | ₹603.65 |
| 2028 | ₹743.57 | +25.02% | ₹754.72 |
| 2029 | ₹896.48 | +20.56% | ₹909.93 |
| 2030 | ₹979.28 | +9.23% | ₹993.97 |
| 2031 | ₹1,140.83 | +16.49% | ₹1,157.94 |
| 2032 | ₹1,223.00 | +7.2% | ₹1,241.34 |
| 2033 | ₹1,392.06 | +13.82% | ₹1,412.94 |
| 2034 | ₹1,562.20 | +12.22% | ₹1,585.63 |
| 2035 | ₹1,612.45 | +3.21% | ₹1,736.89 |
| 2036 | ₹1,793.99 | +11.25% | ₹1,820.90 |
| 2037 | ₹1,851.27 | +3.19% | ₹1,908.52 |
| 2038 | ₹2,040.55 | +10.22% | ₹2,080.15 |
| 2039 | ₹2,044.16 | +0.17% | ₹2,251.78 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Sequent Scientific Brief Company Overview
Sequent Scientific Limited: A Global Animal Health Leader Established in 1985, Sequent Scientific Limited is a renowned animal health company with a global presence. Headquartered in Mumbai, India, the company operates in the animal health business worldwide. Sequent...
Scientific's diverse product range includes animal health active pharmaceutical ingredients (APIs) formulations, such as anthelmintics, anti-protozoals, and nonsteroidal anti-inflammatory drugs. The company also provides analytical solutions for various industries, including API, pharmaceutical, personal care, and nutraceuticals. Sequent Scientific is committed to providing high-quality products and services to its customers. The company's reputation for innovation and excellence has made it a trusted partner in the animal health industry.Sequent Scientific Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 2,735.55 Crore | Market valuation of Sequent Scientific's shares. |
| Revenue (TTM) | 1,380.68 Crore | Total revenue generated by Sequent Scientific over the past twelve months. |
| Net Income (TTM) | -35.86 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +4.92% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | -2.6% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-1.5% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-0.78% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
68.4 | Company's total debt divided by total shareholder equity. |
| Total Debt | 487.69 Crore | Sum of Sequent Scientific's current & long-term financial obligations. |
| Total Cash | 72.44 Crore | Total amount of liquid funds available to Sequent Scientific. |
Is Sequent Scientific A Good Buy For Long Term?
Sequent Scientific, with a small market cap, has faced recent financial challenges. Despite a -20.56% return in the past three months and a negative profit margin, it has historically delivered strong returns. While its revenue dipped -1.5% last quarter, its earnings growth compared to last year remains positive. Its debt and cash balance also provide context. Given these factors, Sequent Scientific may be a moderate long-term buy for investors tolerant of risk and seeking potential growth.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
